Evolus, Inc.

Evolus, Inc. is a performance beauty company that specializes in the aesthetics market by offering innovative, consumer-focused brands. Their flagship product, Jeuveau®, targets cosmetic enhancements for adults seeking to improve their appearance. Founded in 2012 and headquartered in Irvine, California, Evolus, Inc.

is focused on developing aesthetic products. The company has not undergone significant pivots or changes in business operations. François Hutteau is the founder, and David Moatazedi currently serves as CEO. Evolus has raised a total of USD 85.

50 mn through various funding rounds, with the most recent funding being a Private Placement/Follow-on amounting to USD 85. 50 mn, finalized on December 14, 2021. Evolus is recognized for its cash-pay aesthetics emphasis, providing a range of consumer products aimed at enhancing beauty. The flagship product, Jeuveau®, is a proprietary neurotoxin designed to temporarily smooth moderate to severe frown lines in adults.

Jeuveau® has consistently been noted as the fastest-growing neurotoxin in the U. S. for four years. Additionally, Evolus is set to launch Evolysse™, a next-generation hyaluronic acid product aimed at treating dynamic facial wrinkles, utilizing Cold-X™ Technology.

The company's direct-to-consumer approach allows it to reach both healthcare providers and individual consumers across the U. S. For the year 2024, Evolus reported a revenue of USD 264. 31 mn.

In the same year, the company's EBITDA was USD -29. 11 mn, highlighting its financial performance within the aesthetics market. Evolus plans to leverage recent funding to support the launch of its next-generation product, Evolysse™, aiming for a release in the upcoming year. The funding from Pharmakon Advisors, which includes a senior secured term loan of up to USD 125 mn, will assist in the company's recapitalization and growth.

Evolus aims to expand its reach into new geographic markets, solidifying its position in key regions of the U. S. by the end of 2023.